Blocking TRPA1 in Respiratory Disorders: Does It Hold a Promise?

Area of Science:

• Respiratory Medicine
• Neuroscience
• Pharmacology

Background:

• The Transient Receptor Potential Ankyrin 1 (TRPA1) ion channel is abundant in the respiratory tract's C fibers and non-neuronal cells.
• TRPA1 acts as a chemosensor, detecting irritants and mediators involved in airway inflammation and symptoms such as chronic cough, asthma, COPD, allergic rhinitis, and cystic fibrosis.
• Chronic activation of TRPA1 by elevated ligands and inflammatory mediators contributes to persistent airway conditions.

Approach:

• This review synthesizes in vitro, animal, and human evidence supporting TRPA1's role in airway sensory responses.
• It examines the preclinical and clinical development of selective TRPA1 antagonists for respiratory diseases.

Key Points:

• TRPA1's expression throughout the respiratory tract highlights its significance in airway physiology and pathology.
• Evidence links TRPA1 activation to key inflammatory pathways and sensory disturbances in various respiratory conditions.
• Selective TRPA1 antagonists have demonstrated promising results in preclinical models of respiratory diseases.

Conclusions:

• TRPA1 plays a critical role in modulating airway sensory responses and inflammation.
• Targeting TRPA1 represents a potential novel therapeutic strategy for respiratory diseases.
• While no TRPA1 antagonists are currently approved for respiratory conditions, ongoing research and development show significant therapeutic potential.